Latest Amgen Stories
An observational study involving 629 subjects finds rapid, significant, readily-observable improvement in stroke and traumatic brain injury patients following the perispinal administration of Enbrel. (PRWEB) January 02, 2013 Neurological Wellness Center began holding perispinal injection technique training courses in the spring of 2011. Since then physicians, nurses and lay caregivers have come from around the world to their Center in Managua Nicaragua for individualized instructional...
The Perispinal Enbrel Injection Procedure that Dramatically Reverses the Cognitive Deficits and Physical Impairments Caused by Alzheimer’s Disease, Stroke and Traumatic Brain Injury is Now Available in a $49 On-Line Course Offered by http://www.neurological-recovery-guide.com (PRWEB) December 19, 2012 Neurological Wellness Center began holding perispinal injection technique training courses in the spring of 2011. Since then physicians, nurses and lay caregivers have come from around...
To buy Enbrel cheap at the lowest price for genuine Enbrel in North America visit: http://www.genuine-enbrel-cheaper.com. Harmony, California (PRWEB) December 19, 2012 Membership in the newly launched Enbrel Buyer's Club is free. Members purchase Enbrel through Direct Prescription Service (DPS), a full service on-line pharmacy service located in Winnipeg, Manitoba Canada. All Enbrel is the genuine product manufactured for Amgen/Pfizer by Immunex Corporation in California. DPS...
WASHINGTON, Dec. 19, 2012 /PRNewswire/ -- Sanford Heisler, LLP, a leading public interest law firm, today announced a $762 million global qui tam settlement with Amgen, Inc. and the United States Department of Justice. The settlement includes a $612 million civil settlement, a $14 million forfeiture and $136 million in criminal fines. Headquartered in Thousand Oaks, CA, Amgen is a leading human therapeutics company in the biotechnology industry. The whistleblower ("relator") who...
THOUSAND OAKS, Calif., Dec. 19, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it has finalized a settlement agreement with the U.S. government, 49 states and the District of Columbia related to previously disclosed investigations. Amgen will pay approximately $612 million to resolve its civil liability related to certain promotional practices related to the drugs Aranesp(®) (darbepoetin alfa), EPOGEN(®) (epoetin alfa), NEUPOGEN(® )(Filgrastim), Neulasta(®...
WASHINGTON, Dec. 18, 2012 /PRNewswire/ -- Sanford Heisler, LLP, a leading public interest law firm, today announced a $762 million global qui tam settlement with Amgen, Inc. and the United States Department of Justice. The settlement includes a $612 million civil settlement, a $14 million forfeiture and $136 million in criminal fines. Headquartered in Thousand Oaks, CA, Amgen is a leading human therapeutics company in the biotechnology industry. The whistleblower ("relator")...
THOUSAND OAKS, Calif., Dec. 13, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of Robert A. Eckert, former chief executive officer at Mattel, Inc., to its Board of Directors. Mr. Eckert will serve on the Audit and Corporate Responsibility and Compliance Committees of the Board. Following the appointment of Mr. Eckert and the previously announced retirement of Kevin W. Sharer from the Board on Dec. 31, 2012, the Board on Jan. 1, 2013, will be comprised of 14...
THOUSAND OAKS, Calif., Dec. 13, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced appointments to its Board of Directors. Robert A. Bradway, chief executive officer, has been appointed chairman of the Board, and Vance D. Coffman, an Amgen director since 2007, has been appointed lead independent director, both effective on Jan. 1, 2013. As previously announced, Kevin W. Sharer is retiring from the Board, effective Dec. 31, 2012. "On behalf of the Board and all of Amgen,...
THOUSAND OAKS, Calif., Dec. 13, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.47 per share dividend for the first quarter of 2013. The dividend will be paid on March 7, 2013, to all stockholders of record as of the close of business on Feb. 13, 2013. This represents an approximate 31 percent increase from that paid in each of the previous four quarters. Amgen's Board of Directors also approved an increase in share repurchase...
PALO ALTO, Calif., Dec. 12, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today the publication of a clinical trial abstract in the proceedings of the 54(th) Annual Meeting of the American Society of Hematology in Atlanta, Georgia. The abstract, "Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, for Treatment of Patients with Myeloid Growth Factor-Resistant Idiopathic Chronic Neutropenia (ICN)," by Roger M. Lyons, MD; Sharon T. Wilks, MD;...
